Depression in primary care

Ethnicity and Disease

Volumn 17, Issue 2, 2007, Pages

  Elliott, Richard L ^a  

^a MERCER UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Depression; Primary care; STAR*D; Treatment resistant depression

Indexed keywords

AMFEBUTAMONE; BUSPIRONE; CITALOPRAM; CLONAZEPAM; DULOXETINE; ESCITALOPRAM; FLUOXETINE; HYPNOTIC AGENT; MIRTAZAPINE; NORTRIPTYLINE; PAROXETINE; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

AGRANULOCYTOSIS; ANXIETY DISORDER; BRAIN DEPTH STIMULATION; CARDIOVASCULAR DISEASE; CHRONIC PAIN; CLINICAL TRIAL; COMORBIDITY; CONFERENCE PAPER; DEPRESSION; DIABETES MELLITUS; DIAGNOSTIC ACCURACY; ELECTROCONVULSIVE THERAPY; HUMAN; HYPERTENSION; PREVALENCE; PRIMARY MEDICAL CARE; PSYCHOTHERAPY; RISK FACTOR; SEIZURE; SIDE EFFECT; STROKE; SUBSTANCE ABUSE; SYMPTOM; TRANSCRANIAL MAGNETIC STIMULATION; VAGUS NERVE STIMULATION; WEIGHT GAIN;

ANTIDEPRESSIVE AGENTS; DEPRESSION; FEMALE; HUMANS; MALE; PRIMARY HEALTH CARE; UNITED STATES;

EID: 34447540032     PISSN: 1049510X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (24)

1. Depression Guideline Panel: Clinical Practice Guideline 5: Depression in Primary Care. Rockville, MD: US Department of Health and Human Services; 1993.
2. Das S, O'Keefe JH. Behavioral cardiology: recognizing and addressing the profound impact of psychosocial stress on cardiovascular health. Curr Atheroscler Rep. 2006;8:111-118.
3. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:937-952.
4. Frasure-Smith N, Lesperance F, Talajic M. Depression and 18-month prognosis after myocardial infarction. Circulation. 1995; 15;91:999-1005.
5. Whooley MA. Depression and cardiovascular disease. Healing the broken-hearted. JAMA. 2006;295:2874-2881.
6. Pyne JM, Rost KM, Zhang M, et al. Cost-effectiveness of a primary care depression intervention. J Gen Intern Med. 2003;18: 432-441.
7. Murray JL, Lopez AD, eds. Global Burden of Disease. Cambridge, Mass: Harvard University Press; 1996.
8. Luoma JB, Martin CE, Pearson JL. Contact with mental health and primary care providers before suicide: a review of the evidence. Am J Psychiatry. 2002;159:909-916.
9. Goldman LS, Nielsen NH, Champion HC. Awareness, diagnosis, and treatment of depression. J Gen Intern Med. 1999;14:569-580.
10. Whooley MA, Avins AL, Miranda J, Browner WS. Case-finding instalments for depression. Two questions are as good as many. J Gen Intern Med. 1997;12:439-445.
11. Stovall J, Domino FJ. Approaching the suicidal patient. Am Fam Physician. 2003; 68:1814-1818.
12. Gussekloo J, van Exel E, de Craen AJ, Meinders AE, Frolich M, Westendorp RG. Thyroid status, disability and cognitive function, and survival in old age. JAMA. 2004;292:2591-2599.
13. Fountoulakis KN, Iacovides A, Grammaticos P, St Kaprinis G, Bech P. Thyroid function in clinical subtypes of major depression: an exploratory study. BMC Psychiatry. 2004;15: 4-6.
14. Schroder CM, O'Hara R. Depression and obstructive sleep apnea (OSA). Ann Gen Psychiatry. 2005:4:13.
15. Raison CL, Demetrashvili M, Capuron L, Miller AH. Neuropsychiatric adverse effects of interferon-alpha: recognition and management. CNS Drugs. 2005;19:105-123.
16. Patten SB, Love EJ. Can drugs cause depression? A review of the evidence. J Psychiatry Neurosci. 1993;92-102.
17. Das AK, Olfson M, McCurtis HL, Weissman MM. Depression in African Americans: breaking barriers to detection and treatment. J Fam Pract. 2006;55:30-39.
18. Greenberg RM, Kellner CH. Electroconvulsive therapy: a selected review. Am J Geriatr Psychiatry. 2005;13:268-281.
19. Nemeroff CB, Mayberg HS, Krahl SE, et al. VNS therapy in treatment-resistant depression: clinical evidence and putative neurobiological mechanisms. Neuropsychopharmacology. 2006;(7):1345-1355, Erratum in: Neuropsychopharmacology. 2006; (10): 2329.
20. Loo CK, Mitchell PB. A review of the efficacy of transcranial magnetic stimulation (TMS) treatment for depression, and current and future strategies to optimize efficacy. J Affect Dis. 2005;88:255-267.
21. Rush AJ, Fava M, Wisniewski SR, et al. Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials. 2004;25:119-142.
22. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163:28-40.
23. Rush AJ, Trivedi MH, Wisniewski SR, et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med. 2006;354:1231-1242.
24. Trivedi MH, Fava M, Wisniewski SR, et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med. 2006;354:1243-1252.